STOCK TITAN

LOBE SCIENCES LTD - $LOBEF STOCK NEWS

Welcome to our dedicated page for LOBE SCIENCES news (Ticker: $LOBEF), a resource for investors and traders seeking the latest updates and insights on LOBE SCIENCES stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LOBE SCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LOBE SCIENCES's position in the market.

Rhea-AI Summary
Lobe Sciences Ltd. (LOBEF) achieved significant milestones in 2023, including the acquisition and commercial launch of Altemia for Sickle Cell Disease, recording $1.1M CAD in sales, and completing the first-in-man clinical study on L-130, demonstrating improved pharmacokinetics and stability. The company also transitioned to focus on treating Orphan Diseases and appointed a new COO and President for Altemia. Management plans to build on this momentum in 2024 and will be meeting with prospective investors and corporate partners during the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) announced significantly increased bioavailability for its stable psilocin compared to psilocybin in the Phase 1 study of its lead clinical program, L-130. The study confirmed the improved pharmacokinetics of L-130, offering significant therapeutic advantages over other psilocybin formulations. Full results are expected to be published in peer-reviewed journals in the first half of 2024. Lobe Sciences plans to initiate its Phase 2 study in chronic cluster headache in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
-
Rhea-AI Summary
Lobe Sciences Ltd. (LOBEF) announces that its lead clinical asset, L-130, a stabilized psilocin conjugate drug candidate, has surpassed the 12-month stability milestone with no signs of degradation. This achievement is significant as no other psilocin manufacturer has reported a formulation stable enough to be administered in a shelf-stable orally available form. L-130 offers therapeutic advantages over psilocybin formulations, potentially providing faster onset time, improved dosing consistency, increased bioavailability, and reduced side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
Rhea-AI Summary
Lobe Sciences appoints Mathew Lee as Chief Financial Officer, aiming to achieve business goals and support commercial activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
management
-
Rhea-AI Summary
Lobe Sciences signed an amendment to acquire Altemia, including assets and intellectual property, to manage patients with Sickle Cell Disease. 76,000,000 Lobe Shares will be returned and cancelled, and reissued upon achievement of milestones. Altemia members can designate third parties to receive released shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-92.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
LOBE SCIENCES LTD

OTC:LOBEF

LOBEF Rankings

LOBEF Stock Data

1.16M
77.48M
2.4%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver